{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:10:02Z","timestamp":1762341002876},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ijantimicag.2017.01.042","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T06:45:08Z","timestamp":1496645108000},"page":"252-254","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Role of second-line injectable antituberculosis drugs in the treatment of MDR\/XDR tuberculosis"],"prefix":"10.1016","volume":"50","author":[{"given":"Fanny","family":"Quenard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre Edouard","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Drancourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Brouqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0010","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/S2214-109X(14)70361-4","article-title":"The WHO 2014 global tuberculosis report\u2014further to go","volume":"3","author":"Zumla","year":"2015","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0015","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/S0140-6736(16)30729-2","article-title":"WHO recommendations on shorter treatment of multidrug-resistant tuberculosis","volume":"387","author":"Sotgiu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0020","series-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0025","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/jac\/dku438","article-title":"Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study","volume":"70","author":"Cambau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0030","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1183\/09031936.00044812","article-title":"Hearing loss in patients on treatment for drug-resistant tuberculosis","volume":"40","author":"Seddon","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0035","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/1471-2334-14-542","article-title":"Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss","volume":"14","author":"Modongo","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/644591a8-8ae6-450e-974e-1cd1f08f52c7","article-title":"Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa","volume":"8","author":"Shean","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0045","first-page":"622","article-title":"Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis","volume":"6","author":"de Jager","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0050","first-page":"1314","article-title":"Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia","volume":"11","author":"Shin","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0055","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.4065\/81.9.1159","article-title":"The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies","volume":"81","author":"Maki","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.amjmed.2014.01.001","article-title":"PICC-associated bloodstream infections: prevalence, patterns, and predictors","volume":"127","author":"Chopra","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0065","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1473-3099(13)70266-4","article-title":"Management of infections related to totally implantable venous-access ports: challenges and perspectives","volume":"14","author":"Lebeaux","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12959-015-0052-2","article-title":"Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients","volume":"13","author":"Sriskandarajah","year":"2015","journal-title":"Thromb J"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0075","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/jso.24220","article-title":"Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: a prospective study on the incidence of complications and overall failures","volume":"113","author":"Bertoglio","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","article-title":"Inhaled antibiotics for lower airway infections","volume":"11","author":"Quon","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1086\/317524","article-title":"Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis","volume":"32","author":"Sacks","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0090","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/322725","article-title":"Clinical and microbiological efficacy of adjunctive salvage therapy with inhaled aminoglycosides in a patient with refractory cavitary pulmonary tuberculosis","volume":"33","author":"Parola","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0095","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(16)32071-2","article-title":"WHO recommendations for multidrug-resistant tuberculosis","volume":"388","author":"Berry","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2017.01.042_bib0100","first-page":"594","article-title":"[A case of multidrug-resistant pulmonary tuberculosis]","volume":"38","author":"Tsurutani","year":"2000","journal-title":"Nihon Kokyuki Gakkai Zasshi"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T08:48:46Z","timestamp":1530694126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917301784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0924857917301784"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.042","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of second-line injectable antituberculosis drugs in the treatment of MDR\/XDR tuberculosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}